810 results on '"D'Arena, Giovanni"'
Search Results
2. Behaviour and fate of Ag-NPs, TiO2-NPs and ZnO-NPs in the human gastrointestinal tract: Biopersistence rate evaluation
3. Cognitive Health of Nonagenarians in Southern Italy: A Descriptive Analysis from a Cross-Sectional, Home-Based Pilot Study of Exceptional Longevity (Cilento Initiative on Aging Outcomes Or CIAO).
4. What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study
5. SARS-COV2 Infection in Vaccinated Patients: Look for Clinical History and Test Humoral Immunity
6. Comparison of cardiovascular disease and cancer prevalence between Mediterranean and north European middle-aged populations (The Cilento on Ageing Outcomes Study and The Malmö Offspring Study)
7. T-Large Granular Lymphocytic Leukemia with Hepatosplenic T-Cell Lymphoma? A Rare Case of Simultaneous Neoplastic T-Cell Clones Highlighted by Flow Cytometry and Review of Literature.
8. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients
9. Internalization of Pegylated Er:Y2O3 Nanoparticles inside HCT-116 Cancer Cells: Implications for Imaging and Drug Delivery
10. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
11. What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.
12. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling
13. P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
14. P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
15. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
16. Preliminary analysis of double‐negative T, double‐positive T, and natural killer T‐like cells in B‐cell chronic lymphocytic leukemia
17. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands
18. Internalization of Pegylated Er:Y2O3 Nanoparticles inside HCT-116 Cancer Cells: Implications for Imaging and Drug Delivery.
19. Supplementary Data from TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
20. Data from Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network
21. Supplementary Table 1, Figures 1-4 from Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network
22. Measurable residual disease in chronic lymphocytic leukemia
23. The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
24. Polycyclic aromatic hydrocarbons in Haliotis tuberculata (Linnaeus, 1758) (Mollusca, Gastropoda): Considerations on food safety and source investigation.
25. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments
26. First data on trace elements in Haliotis tuberculata (Linnaeus, 1758) from southern Italy: Safety issues
27. Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association
28. An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
29. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report
30. Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
31. A Multi-Parametric and Multi-Layer Study to Investigate the Largest 2022 Hunga Tonga–Hunga Ha’apai Eruptions
32. Potential Mechanisms by which Glucocorticoids Induce Breast Carcinogenesis through Nrf2 Inhibition
33. Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma
34. The Last exhibition of the Italian Colonial Empire: Naples 1938–40
35. Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia
36. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response
37. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders
38. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
39. Design and Development of the New Diagnostics Control System for the SPES Project at INFN-LNL
40. Pysmlib: A Python Finite State Machine Library for EPICS
41. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets
42. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics
43. Dietary exposure of zinc oxide nanoparticles (ZnO-NPs) from canned seafood by single particle ICP-MS: Balancing of risks and benefits for human health
44. Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry
45. Meningeal Involvement in Primary Plasma Cell Leukemia
46. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
47. Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia
48. SARS-COV2 Infection in Vaccinated Patients: Look for Clinical History and Test Humoral Immunity
49. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
50. CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.